Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Revacept, a Novel Inhibitor of Platelet Adhesion in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Interventions: a Phase II, Multicentre, Randomised, Double-blind and Placebo-controlled Study

NCT03312855 is registered in ClinicalTrials.gov with Deutsches Herzzentrum Muenchen as lead sponsor.

NCT NCT03312855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03312855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Revacept, a Novel Inhibitor of Platelet Adhesion in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Interventions: a Phase II, Multicentre, Randomised, Double-blind and Placebo-controlled Study
Lead sponsor
Deutsches Herzzentrum Muenchen
Phase
Phase 2
Overall status
Completed
Start date
November 20, 2017
Completion date
March 26, 2020
Enrollment
334 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

stable coronary artery disease